Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102918 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL7508072 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL7508080 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL31167604 | 0.92 | GPR52 (0.61) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL11813974 | 0.83 | GPR52 (0.56) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL1348921 | 0.83 | GPR52 (0.56) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL11813977 | 0.83 | GPR52 (0.56) | ALDH1A1MAPTHTTNPSR1LMNA | |
| SCHEMBL7568121 | 0.81 | GPR52 (0.51) | ALDH1A1MAPTHTTNPSR1HPGD | |
| SCHEMBL14705712 | 0.81 | MAOB (0.68) | ALDH1A1MAPTLMNAHPGDGPR52 | |
| SCHEMBL28420401 | 0.81 | MAOB (0.68) | ALDH1A1MAPTLMNAHPGDGPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| EP-0138349-B1 | 3-BENZOYL-2-MERCAPTOPROPIONIC ACID DERIVATIES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4594197-A | 3-benzoyl-2-mercaptopropionic acid derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1986-06-10 | — | — | US | disclosed |
| EP-0138349-A1 | 3-Benzoyl-2-mercaptopropionic acid derivaties | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ALDH1A1 1004/4885MAPT 3619/4885HTT 3894/4885 |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ALDH1A1 263/4885MAPT 4075/4885HTT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.